Skip to search formSkip to main contentSkip to account menu

PR-171

An epoxomicin derivate with potential antineoplastic activity. PR-171 irreversibly binds to and inhibits the chymotrypsin-like activity of the 20S… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Abstract A phase 1 study with carfilzomib and vorinostat was conducted in 20 B-cell lymphoma patients. Vorinostat was given… 
Highly Cited
2011
Highly Cited
2011
Carfilzomib [(2S)-N-[(S)-1-[(S)-4-methyl-1-[(R)-2-methyloxiran-2-yl]-1-oxopentan-2-ylcarbamoyl]-2-phenylethyl]-2-[(S)-2-(2… 
Highly Cited
2011
Highly Cited
2011
Carfilzomib (formerly PR-171) is a novel epoxyketone-based irreversible proteasome inhibitor. In preclinical studies, carfilzomib… 
Highly Cited
2010
Highly Cited
2010
Proteasomes degrade most proteins in mammalian cells and are established targets of anti-cancer drugs. The majority of proteasome… 
Highly Cited
2009
Highly Cited
2009
Purpose: Carfilzomib (formerly PR-171) is a novel proteasome inhibitor of the epoxyketone class that is selective and… 
Highly Cited
2007
Highly Cited
2007
Clinical studies with bortezomib have validated the proteasome as a therapeutic target for the treatment of multiple myeloma and… 
Highly Cited
2007
Highly Cited
2007
Proteasome inhibitors represent a new class of antineoplastic drugs that are considered in the treatment of haematological… 
Highly Cited
2007
Highly Cited
2007
Carfilzomib (CFZ) is a structurally- and mechanistically-novel proteasome inhibitor of peptide epoxyketone class that exhibits a… 
2007
2007
Introduction: Carfilzomib (CFZ) is a structurally- and mechanistically-novel proteasome inhibitor (PI) of the peptide epoxyketone…